Skip to content

Genetic and molecular mechanism of intrathecal morphine induced itch in patients with advanced tumors

Genetic and molecular mechanism of intrathecal morphine induced itch in patients with advanced tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088773
Enrollment
Unknown
Registered
2024-08-27
Start date
2024-10-14
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug induced pruritus

Interventions

Part I. Pruritus Group:Intrathecal opioids
Part I. Not Pruritus Group:Intrathecal opioids
Part II. Group:Intrathecal opioids

Sponsors

Zhongshan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Voluntary participation, the patient understands and signs the informed consent form or signed by his immediate family members; 2.Age: 18-80 years old; 3.Tumor etiology; 4.Voluntary endospinal tube analgesia for continuous intrathecal morphine therapy, with no contraindications related to surgery.

Exclusion criteria

Exclusion criteria: 1.History of pruritus: previous skin diseases, chronic urticaria, chemotherapy-related pruritus and erythema, cholestatic pruritus, diabetic pruritus, etc.; 2.Contraindications to endospinal tube analgesia: hypocoagulability (PT prolongation >3s, APTT prolongation >10s, TT prolongation >3s, or platelet <75×10^9/L); Severe hemodynamic instability, history of spinal cord-related diseases such as sepsis, intracranial hypertension, spinal tuberculosis, cerebrospinal fluid outflow, and unsuitable puncture and catheterization such as tumor proximity to the puncture site; 3.Bilirubin and other related biochemical indicators increased; 4.Combined with severe mental illness, severe neurosis, pregnancy, and rheumatic and immunological diseases; 5.Recent allergic events; Patients who have received allogeneic blood transfusion in the past month; 6.Patients who lack consciousness, lack of understanding or expression ability, and cannot complete follow-up; Patients with abnormal limb autonomic mobility disorders or sensory deficits.

Design outcomes

Primary

MeasureTime frame
Sequencing of the opioid receptor MOR;

Secondary

MeasureTime frame
Itching, pain scale scores;

Countries

China

Contacts

Public ContactCang Jing

Zhongshan Hospital Affiliated to Fudan University

cang.jing@zs-hospital.sh.cn+86 139 1601 0421

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026